Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Jasper Therapeutics, Inc.

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.

Abingworth

Alexandria Venture Investments

Amgen

Apeiron Investment Group

Avego Healthcare Capital

Roche Venture Fund

Kingdon Capital

Woodline Partners

Federated Kaufmann Fund

Velan Capital

Qiming Venture Partners USA

Citadel

TSVC

Surveyor Capital

Jasper Therapeutics

Today, Jasper provided a recap its recent accomplishments, including the authorization by the European Medicines Agency of the Company’s Clinical Trial Applications for its Phase 1b/2a BEACON study of briquilimab in CSU and Phase 1b/2a SPOTLIGHT study in CIndU. Read the full announcement here: https://lnkd.in/gcDX6niJ

Results from two studies evaluating briquilimab as a conditioning agent for stem cell transplant were presented at the American Society of Hematology 2023 annual meeting. Read a summary of the results presented here: https://lnkd.in/gJ4GFQGU

Fascinating paper which concluded: A large proportion of CSU patients treated with H1AH-based therapies had uncontrolled disease, contributing to increased HRU and patient burden. Non-responders had more comorbidities and HRU at baseline and follow-up, with steep increases in follow-up hospitalizations relative to baseline, highlighting an urgent need for early disease control.  
At Jasper we are seeking to address this high unmet need. #Jaspertherapeutics

Jasper is pleased to announce that the first patient has been dosed in the Phase 1b/2a BEACON study evaluating briquilimab in CSU

Read the full announcement here: https://lnkd.in/gX4DNe7h

The Jasper team wishes everyone a restful and joyful Thanksgiving holiday!

Jasper is excited to participate in the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Meeting. Tomorrow at 3:45pm PT Charles C. will be presenting preclinical data demonstrating that briquilimab prevents passive systemic anaphylaxis in mice expressing chimeric human/mouse CD117 during the “Meet the Authors” poster session in Exhibition Hall C (Level 1). View the poster here: https://lnkd.in/gc9aQ5Es

CSU affects 40 million people worldwide, and around 60% need an option beyond standard-of-care antihistamines, according to Novartis.  As a clinician, it is exciting to see potential new medicines coming into clinic for patients with high unaddressed needs.

https://lnkd.in/g9-qEBKj

Jasper is pleased to report third quarter 2023 financial results. Read the full announcement here: https://lnkd.in/greDRAD4

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023.

Read the full announcement here: https://lnkd.in/dsf4EK7S

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables		1.42M -	3.92M 176.57%	1.77M 54.89%	4.15M 134.67%
accumulated other comprehensive income loss			-93.65M -
cash and cash equivalents		19.84M -	84.70M 326.96%	38.25M 54.84%	86.89M 127.16%
cash and short term investments	100.15M -	19.84M 80.19%	84.70M 326.96%	38.25M 54.84%	86.89M 127.16%
common stock		1K -	4K 300%	4K 0%	1K 75%
deferred revenue			2.81M -
deferred revenue non current					-2.26M -
deferrred tax liabilities non current					488K -
goodwill
goodwill and intangible assets					-1 -
intangible assets
inventory		95.47K -
long term debt		1.62M -	2.38M 46.55%	2.79M 17.06%	1.81M 34.89%
long term investments					417K -
net debt		-18.21M -	-81.82M 349.19%	-34.60M 57.71%	-84.10M 143.07%
net receivables		600K -		663K -	250K 62.29%
other assets					1 -
other current assets		151.53K -	3.13M 1,965.62%	2.82M 9.97%	1.80M 36.09%
other current liabilities		2.60M -	785K 69.75%	4.43M 464.59%	7.25M 63.65%
other liabilities					1 -
other non current assets		643K -	990K 53.97%	1.18M 18.79%	1.34M 14.20%
other non current liabilities		52.85M -	13.74M 74.01%	2.52M 81.65%	2.26M 10.19%
othertotal stockholders equity		1.68M -	136.96M 8,042.93%	92.76M 32.27%	248.04M 167.40%
preferred stock			93.65M -	48.36M 48.36%
property plant equipment net		2.03M -	4.83M 138.20%	5.45M 12.85%	4.19M 23.10%
retained earnings		-36.81M -	-67.45M 83.22%	-105.14M 55.87%	-169.60M 61.32%
short term debt			505K -	865K 71.29%	972K 12.37%
short term investments	100.15M -
tax assets					488K -
tax payables		4.55K -
total assets	100.15M -	23.36M 76.68%	93.65M 300.97%	48.36M 48.36%	95.38M 97.23%
total current assets	100.15M -	20.68M 79.35%	87.83M 324.61%	41.73M 52.49%	88.94M 113.12%
total current liabilities		4.01M -	8.02M 99.90%	7.07M 11.91%	12.37M 75.15%
total debt		1.62M -	2.88M 77.65%	3.65M 26.55%	2.79M 23.69%
total investments	100.15M -				417K -
total liabilities		58.49M -	24.14M 58.73%	12.37M 48.74%	14.68M 18.62%
total liabilities and stockholders equity	100.15M -	23.36M 76.68%	93.65M 300.97%	48.36M 48.36%	95.38M 97.23%
total non current assets		2.67M -	5.82M 117.93%	6.63M 13.86%	6.44M 2.84%
total non current liabilities		54.48M -	16.12M 70.42%	5.31M 67.07%	2.30M 56.62%
total stockholders equity		-35.13M -	69.52M 297.89%	35.99M 48.23%	78.44M 117.96%

COM:JASPERTHERAPEUTICS

Jasper Therapeutics

Last Close

21.84

22/11 21:00

Market Cap

299.75M

Beta: -

Volume Today

95.90K

Avg: -

Preview